Bristol-Myers Squibb, AstraZeneca enter $1 billion diabetes pact

Share this article:
Bristol-Myers Squibb and AstraZeneca announced a collaboration deal worth $1 billion to develop and commercialize two investigational compounds for Type 2 diabetes. The compounds are saxagliptin, a dipeptidyl peptidase-4 inhibitor currently in Phase III development, and dapagliflozin, a sodium-glucose cotransporter-2 inhibitor currently in Phase IIb development. Both compounds were discovered by Bristol-Myers Squibb. Terms of the deal include an upfront payment of $100 million by AstraZeneca to Bristol-Myers Squibb. BMS may also receive additional payments of up to $650 million based on development and regulatory milestones for the two compounds. Additional sales milestones up to $300 million per product are also possible.
Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...